scholarly journals Precision Preventive Medicine of Relapse in Smoking Cessation: Can MRI Inform the Search of Intermediate Phenotypes?

Biology ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 35
Author(s):  
Yolaine Rabat ◽  
Sandra Chanraud ◽  
Majd Abdallah ◽  
Igor Sibon ◽  
Sylvie Berthoz
Keyword(s):  
Smoking Cessation ◽  
Meta Analysis ◽  
Major Health Problem ◽  
Major Health ◽  
Smoking Cessation Treatment ◽  
Intermediate Phenotypes ◽  
Prevention Therapy ◽  
Cessation Treatment ◽  
Magnetic Resonance Imaging Mri

Chronic tobacco smoking remains a major health problem worldwide. Numerous smokers wish to quit but most fail, even if they are helped. The possibility of identifying neuro-biomarkers in smokers at high risk of relapse could be of incredible progress toward personalized prevention therapy. Our aim is to provide a scoping review of this research topic in the field of Magnetic Resonance Imaging (MRI) and to review the studies that investigated if MRI defined markers predicted smoking cessation treatment outcome (abstainers versus relapsers). Based on the available literature, a meta-analysis could not be conducted. We thus provide an overview of the results obtained and take stock of methodological issues that will need to be addressed to pave the way toward precision medicine. Based on the most consistent findings, we discuss the pivotal role of the insula in light of the most recent neurocognitive models of addiction.

scholarly journals Smoking cessation treatment for COPD smokers: the role of counselling

2015 ◽  
Vol 79 (1) ◽  
Author(s):  
C.A. Jiménez-Ruiz ◽  
K.O. Fagerström
Keyword(s):  
Smoking Cessation ◽  
Weight Gain ◽  
Direct Relationship ◽  
Gain Control ◽  
Self Esteem ◽  
Smoking Cessation Treatment ◽  
Quit Attempt ◽  
Previous Diagnosis ◽  
Cessation Treatment

Smoking cessation is the only therapeutic intervention that can prevent COPD smokers from the chronic progression of their disorder. The most important intervention for helping these smokers to quit is a combination of counseling plus pharmacological treatment. The characteristics of the counseling should be different depending if this intervention is offered to smokers with a previous diagnosis of COPD or if the intervention is offered to smokers who have been recently diagnoses with COPD. The counseling of patients who have been recently diagnosed should include: a) explanation of the direct relationship between smoking and COPD, b) encouraging these patients to quit and c) using of spirometry and measurements of CO as a motivational tools. The counseling of patients who have been previously diagnosed should include: a) encouragement to make a serious quit attempt, b) an intervention that increases motivation, self-efficacy and self-esteem, c) and the intervention should also control depression and be directed to weight gain control.

scholarly journals Smoking cessation treatment for COPD smokers: the role of pharmacological interventions

2015 ◽  
Vol 79 (1) ◽  
Author(s):  
C.A. Jiménez-Ruiz ◽  
K.O. Fagerström
Keyword(s):  
Smoking Cessation ◽  
Replacement Therapy ◽  
Nicotine Replacement Therapy ◽  
Cost Effective ◽  
Pharmacological Treatments ◽  
Pharmacological Interventions ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment ◽  
High Doses

Because stopping smoking is such a pressing necessity for COPD smokers physicians should use smoking cessation treatments aggressively. For optimal efficacy smoking cessation in COPD smokers should combine behavioral and pharmacological treatments. Three types of pharmacological treatments are proven to be safe and effective: Nicotine Replacement Therapy (NRT), Bupropion and Varenicline. Use of NRT, bupropion or varenicline, single or in combination, at standard doses or at high doses, for 8-12 weeks or for more than 6-12 months have proven to help these patients to quit. For optimizing efficacy these medications can also be introduced some weeks before actual quitting. In COPD smoking patients that are not interested in stopping completely or abruptly these medications can be used to aid cessation in a more gradual way. Pharmacotherapy to aid cessation in COPD smokers have proven to be highly cost effective.

Nature and Role of Change in Anxiety Sensitivity During NRT-Aided Cognitive-Behavioral Smoking Cessation Treatment

2012 ◽  
Vol 41 (1) ◽  
pp. 51-62 ◽  
Author(s):  
Yaara Assayag ◽  
Amit Bernstein ◽  
Michael J. Zvolensky ◽  
Dan Steeves ◽  
Sherry S. Stewart
Keyword(s):  
Smoking Cessation ◽  
Anxiety Sensitivity ◽  
Cognitive Behavioral ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment

scholarly journals History of smoking cessation treatment in Poland – the strengthening role of cytisine as the most effective and safe pharmacotherapy

2020 ◽  
Vol 6 (2) ◽  
pp. 116-123
Author(s):  
Witold Zatoński ◽  
Kinga Janik-Koncewicz ◽  
Zuzanna Stępnicka ◽  
Katarzyna Zatońska ◽  
Katarzyna Połtyn-Zaradna ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment ◽  
History Of

Effect of BMI on Prolonged Abstinence after Smoking Cessation Treatment: A Retrospective Cohort Study

2021 ◽  
Vol 13 ◽  
Author(s):  
Fernanda Piotto Frallonardo ◽  
Danielle Ruiz Lima ◽  
Carlos Felipe Cavalcanti Carvalho ◽  
Aline Rodrigues Loreto ◽  
Bruna Beatriz Sales Guimarães-Pereira ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Cohort Study ◽  
Regression Models ◽  
Overweight And Obesity ◽  
Baseline Body Mass Index ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment ◽  
Baseline Bmi ◽  
Prolonged Abstinence

Background: Despite the well-documented relationship between weight gain and poorer cessation outcomes among smokers, the role of the former (baseline) weight in smoking cessation is insufficiently investigated. We hypothesized that patients with higher baseline body mass index(BMI) have a worse prognosis in tobacco cessation. Objectives: This retrospective clinical cohort study aimed to investigate the role of the baseline BMI on abstinence over 12 months after participation in smoking cessation treatment conducted in a middle-income country (n = 664). Methods: Data from a 6-week smoking cessation protocol performed in a Psychosocial Care Unit(CAPS) were used. The protocol included four medical consultations and six Cognitive-Behavioral Therapy(CBT) group sessions. Initially, 1,213 participants were evaluated for the study, but only the participants whose telephone contact was successful were included in the outcome analyses. The attrition rate was 45.3%. Continuous and categorical (normal, overweight, and obesity) BMI values were computed. Survival regression models were used to test the associations between BMI and the 12-month abstinence outcome. Self-report 4-week abstinence at the end of treatment was also investigated using logistic regression models. Results: Baseline BMI had no significant effect on both short (4-week-point abstinence) and long (12-month prolonged abstinence) treatment outcomes. Conclusion: The possible influence of the baseline BMI on smoking cessation outcomes, especially considering prolonged abstinence, was not corroborated by our results. Regardless of our results, the detrimental health outcomes due to the combination of obesity/overweight and smoking justify that these subgroups of individuals be continuously targeted for adequate smoking prevention and treatment.

scholarly journals Impact of variation in functions and delivery on the effectiveness of behavioural and mood management interventions for smoking cessation in people with depression: protocol for a systematic review and meta-analysis

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e018617 ◽  
Author(s):  
Gemma Taylor ◽  
Paul Aveyard ◽  
Regina Van der Meer ◽  
Daniel Toze ◽  
Bobby Stuijfzand ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Behaviour Change ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Cochrane Review ◽  
Mood Management ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment ◽  
The Difference ◽  
Randomised Controlled

IntroductionTobacco is the world’s leading preventable cause of disease and death. People with depression are twice as likely to smoke and are less responsive to standard tobacco treatments as compared with the general population. A Cochrane systematic review of randomised controlled trials of smoking cessation treatment for smokers with current or historical depression found that adding mood management to usual smoking treatment improved quit rates. However, the review did not examine if variation in intervention delivery or intervention functions impacted on treatment effectiveness.With the aim of providing information to develop tailored approaches to treating smoking for people with current depression, we will add-on to the Cochrane review in three ways: (1) use the Template for Intervention Description and Replication checklist to determine if variations in mood management delivery have impact on intervention effectiveness, (2) use the Taxonomy of Behaviour Change techniques for smoking cessation to examine which behaviour change functions are most effective for smoking cessation in people with current depression and (3) examine the difference in change in depression scores between intervention and control arms.Methods and analysisWe will include randomised controlled trials of smokers with current depression as identified by a previous Cochrane review and the in-progress update of this Cochrane review. We will use meta-regression to examine (1) if variations in delivery of mood management impact on smoking cessation intervention effectiveness, (2) determine which behaviour change functions are most effective for smoking cessation and (3) use meta-analysis of the difference in change in depression scores between treatment arms from baseline to follow-up to determine if offering smoking cessation treatment causes psychological harm.Ethics anddisseminationEthical approval is not required for this study. We will disseminate the findings of this work at national and international conferences, and to relevant patient panels.PROSPERO registration numberCRD42017070741.

Sign in / Sign up

Export Citation Format

Share Document